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ABSTRACT
ObjeCtive
To assess the between hospital variation in use of 
guideline recommended treatments and clinical 
outcomes for acute myocardial infarction in Sweden 
and the United Kingdom.
Design
Population based longitudinal cohort study using 
nationwide clinical registries.
setting anD partiCipants
Nationwide registry data comprising all hospitals 
providing acute myocardial infarction care in Sweden 
(SWEDEHEART/RIKS-HIA, n=87; 119 786 patients) and 
the UK (NICOR/MINAP, n=242; 391 077 patients), 
2004-10.
Main OutCOMe Measures
Between hospital variation in 30 day mortality of 
patients admitted with acute myocardial infarction.
results
Case mix standardised 30 day mortality from acute 
myocardial infarction was lower in Swedish hospitals 
(8.4%) than in UK hospitals (9.7%), with less variation 
between hospitals (interquartile range 2.6% v 3.5%). 
In both countries, hospital level variation and 30 day 
mortality were inversely associated with provision of 
guideline recommended care. Compared with the 
highest quarter, hospitals in the lowest quarter for use 
of primary percutaneous coronary intervention had 
higher volume weighted 30 day mortality for ST 
elevation myocardial infarction (10.7% v 6.6% in 
Sweden; 12.7% v 5.8% in the UK). The adjusted odds 
ratio comparing the highest with the lowest quarters 
for hospitals’ use of primary percutaneous coronary 
intervention was 0.70 (95% confidence interval 0.62 to 
0.79) in Sweden and 0.68 (0.60 to 0.76) in the UK. 
Differences in risk between hospital quarters of 
treatment for non-ST elevation myocardial infarction 
and secondary prevention drugs for all discharged 
acute myocardial infarction patients were smaller than 
for reperfusion treatment in both countries.
COnClusiOn
Between hospital variation in 30 day mortality for 
acute myocardial infarction was greater in the UK than 
in Sweden. This was associated with, and may be 
partly accounted for by, the higher practice variation in 
acute myocardial infarction guideline recommended 
treatment in the UK hospitals. High quality healthcare 
across all hospitals, especially in the UK, with better 
use of guideline recommended treatment, may not 
only reduce unacceptable practice variation but also 
deliver improved clinical outcomes for patients with 
acute myocardial infarction.
CliniCal trials registratiOn
 Clinical trials NCT01359033.
Introduction
Variation between hospitals in quality of care and 
 clinical outcomes provides useful insight into the per-
formance of national health systems.1-8  Considerable 
attention has focused on acute myocardial infarc-
tion,3-10  which remains the leading cause of cardiovas-
cular death worldwide. Within country studies have 
reported declining between hospital variation in mor-
tality from acute myocardial infarction over recent 
years,3 6 11  but they have been inconsistent in attribut-
ing this to reductions in variation in  practice.4 5  Most 
 studies have reported practice variation and outcomes 
independently and have been limited by lack of popu-
lation coverage, basing their analyses on selected hos-
pitals or on subgroups defined by age or acute 
WhAT IS AlReAdy knoWn on ThIS TopIC
Variation between hospitals in quality of care and clinical outcomes provides useful 
insight into the performance of national health systems
A significant difference in patients’ 30 day mortality after acute myocardial 
infarction between Sweden and the UK has been reported
International comparisons of between hospital variation and its association with 
acute myocardial infarction mortality remain absent
WhAT ThIS STudy AddS
Hospitals’ 30 day mortality rates for acute myocardial infarction and between 
hospital variation in mortality were greater in the UK than in Sweden
This was associated with, and may be partly accounted for by, the greater variation 
in practice as regards guideline recommended treatment for acute myocardial 
infarction in the UK hospitals
More consistent healthcare across all hospitals with better use of guideline 
recommended treatment may not only reduce practice variation but also deliver 
improved clinical outcomes for patients with acute myocardial infarction
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myocardial infarction phenotype (either ST elevation 
myocardial infarction  or non-ST elevation myocardial 
infarction).3-5 9 10
To date, analyses of between hospital variation in 
the treatment and outcomes of acute myocardial 
infarction have been conducted within countries; 
although this has provided information about 
national scope for improvement in health systems, it 
has been uninformative about systems’ performance 
relative to other countries. This represents an import-
ant missed opportunity for learning from other 
healthcare systems and for international benchmark-
ing of performance. Here, we report the variation 
between hospitals in the treatment and outcomes of 
patients with acute myocardial infarction in Sweden 
and the United Kingdom (England and Wales), the 
only two countries in the world with continuous 
national quality of care and outcome registries for 
acute myocardial infarction in which all hospitals 
participated.12 13 The comparison was facilitated and 
made more relevant by the similarity of the health 
systems in the two countries, both of which provide 
tax funded universal care free at the point of contact.
We have previously reported a significant difference 
in patients’ 30 day mortality after acute myocardial 
infarction between Sweden and the UK,14 and the differ-
ence in mortality reduced with time. We have now 
sought to determine whether between hospital varia-
tion in acute myocardial infarction care and clinical 
outcomes also differ between the two countries. Our 
specific objectives were to compare Sweden and the UK 
in terms of between hospital variation in the use of 
guideline recommended treatment for acute myocardial 
infarction and the crude and case mix standardised 30 
day mortality. We investigated possible time trends, 
sources of between hospital variation, and potential 
benefits of targeting between hospital variation for bet-
ter adherence to guideline recommended treatment to 
improve survival of patients with acute myocardial 
infarction.
Methods
eligible hospitals and patients
We included all acute hospital units providing care for 
patients with acute myocardial infarction in Sweden 
(n=87) and in England and Wales (n=242). Eligible 
patients (119 786 patients in Sweden and 391 077 
patients in the UK) were aged at least 30 years and 
admitted between 1 January 2004 and 31 December 
2010. The diagnosis of acute myocardial infarction was 
based on guidelines from the European Society of Car-
diology, American College of Cardiology, and American 
Heart Association.15  For multiple admissions of the 
same patient, we used the earliest record. Details of 
data validation,12 13  patient population, data quality 
and completeness, and comparability of variable defini-
tions regarding acute myocardial infarction diagnosis, 
patient case mix, evidence based hospital treatment 
strategies, and discharge drug variables in SWEDE-
HEART/RIKS-HIA and MINAP were described in the pre-
vious study.14 
Case mix variables
The 17 case mix measures were demographic factors 
(age, sex, year of hospital admission); risk factors 
(smoking, history of diabetes and hypertension); 
severity of acute myocardial infarction (troponin I or T 
concentration, systolic blood pressure and heart rate 
at admission to hospital, and cardiac arrest); history 
of previous heart failure, cerebrovascular disease, and 
acute myocardial infarction; and procedure and drug 
use before admission (antiplatelet treatment with 
aspirin, clopidogrel, or both; previous percutaneous 
coronary intervention and coronary artery bypass 
graft).
guideline recommended treatment
Class 1 guideline recommended treatment included 
reperfusion treatment (primary percutaneous coronary 
intervention, any fibrinolytic treatment) for patients 
with ST elevation myocardial infarction; revascularisa-
tion (percutaneous coronary intervention or coronary 
artery bypass graft) as appropriate and feasible, and 
anticoagulant (unfractionated heparin, low molecular 
weight heparin, or Fondaparinux) for patients with 
non-ST elevation myocardial infarction; and, for 
patients with acute myocardial infarction who survived 
to hospital discharge, the use of antiplatelet treatment 
(single or dual antiplatelet), β blockers, angiotensin 
converting enzyme inhibitors or angiotensin receptor 
blockers, and 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors (statins).16-19
Mortality outcomes
The primary clinical outcome was all cause mortality 
within 30 days of hospital admission. Each country has 
a national unique identifier which we used to link 
patients with the National Population Registry (in Swe-
den) and the Office for National Statistics (in the UK) to 
ascertain vital status and date of death (available for 
99.3% and 98.7% of patients, respectively).
statistical analysis
We compared the crude hospital proportions of case 
mix, treatments, and 30 day mortality by year of hospi-
tal admission. We initially investigated the hospital 
trajectories of these proportions graphically by using 
panel plots. We derived hospitals’ use of treatments 
and 30 day mortality rates from patient data and 
weighted them by each hospital’s total volume of 
patients with acute myocardial infarction, overall and 
by admission year.
As the hospital rates were not normally distributed, 
we used the interquartile range to describe the observed 
variation. To account for patient case mix in investigat-
ing variation in hospital practice, we constructed case 
mix models for each of the guideline recommended 
treatments and 30 day mortality by using the 17 
 variables described above. Using these models, we esti-
mated the predicted probability of receipt of guideline 
recommended treatments and death at 30 days after 
hospital admission for each patient and summarised 
these at the hospital level to obtain the expected 
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 hospital proportions. For each hospital, we divided the 
observed mortality by the expected hospital 30 day 
mortality to obtain the hospital standardised mortality 
ratio. We determined hospitals’ case mix standardised 
30 day mortality rates by multiplying each hospital’s 
standardised mortality ratio by the crude 30 day mortal-
ity rate for acute myocardial infarction for the respec-
tive country. Likewise, we applied the indirect 
standardisation to obtain case mix standardised hospi-
tal treatment proportions. We estimated the association 
between case mix standardised hospital treatment pro-
portions and standardised hospital mortality by cor-
relation analysis.
To examine the association between hospitals’ vari-
ation in treatments and patients’ risk of 30 day mortal-
ity, we first summarised volume weighted hospital 30 
day mortality rates by quarters of hospital guideline 
recommended care, in which we classified hospitals 
by proportions of treatment use into lowest (first quar-
ter), medium-low (second quarter), medium-high 
(third quarter), and highest (fourth quarter). We fitted 
a multilevel generalised mixed model, adding the vari-
ables of hospital treatment quarters (hospital level 
variables) to the 17 case mix variables (patient level 
variables), to compare the case mix adjusted risk 
ratios between quarters of hospital treatment use and 
mortality risk in Sweden and the UK. The model incor-
porated a hospital random effect to account for clus-
tering of patient data. We evaluated the extent of 
patients with missing data for the case mix variables 
and managed it by multiple imputation (supplemen-
tary appendix 1). We examined the model fit by the 
distribution of Pearson residuals and mean square 
weighted deviation (Pearson χ2 statistic divided by 
degree of freedom) (supplementary appendix 2).20 We 
did analyses separately for each country with a com-
mon protocol, using SAS version 9.0 in London by 
means of secure remote access.
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, and nor were they 
involved in the design and implementation of the study. 
We plan to involve patients in dissemination of the 
study results by inviting patients and their families to 
the study information session hosted at the Farr 
 Institute.
Results
Hospital level case mix
Hospital level measures of infarct severity, including 
heart rate, systolic blood pressure, and troponin con-
centration, were comparable for Sweden and the UK 
(supplementary table A). Compared with hospitals in 
the UK, we observed a higher median proportion of 
female patients (37.0% v 34.6%) and patients with a 
history of diabetes (22.8% v 17.0%) or heart failure 
(9.5% v 5.1%) in Swedish hospitals. Although the pro-
portion of patients with ST elevation myocardial 
infarction was greater in UK hospitals than in Swedish 
hospitals between 2004 and 2007, it was more compa-
rable in 2010 (27.5% (interquartile range 30.5%) v 
31.3% (11.2%), respectively). Hospital volume was 
greater in Sweden than in the UK, with a median of 
2325 in 2004 and 2349 in 2010, compared with 1982 
and 2084 in the UK.
Hospital level treatment
Hospital provision of primary percutaneous coronary 
intervention for ST elevation myocardial infarction 
patients was higher in Sweden (61.9% v 34.9%), and 
variation was much lower (interquartile range 16.7% 
v 50.7%), compared with the UK. Figure 1 shows 
that  in both countries, reduced between hospital 
Primary PCI for STEMI patients (%)
  Sweden 2004
  UK 2004
  Sweden 2007
  UK 2007
  Sweden 2010
  UK 2010
  Sweden 2004-10
  UK 2004-10
Any reperfusion for STEMI patients (%)
  Sweden 2004
  UK 2004
  Sweden 2007
  UK 2007
  Sweden 2010
  UK 2010
  Sweden 2004-10
  UK 2004-10
Anticoagulant for NSTEMI patients (%)
  Sweden 2004
  UK 2004
  Sweden 2007
  UK 2007
  Sweden 2010
  UK 2010
  Sweden 2004-10
  UK 2004-10
Revascularisation for NSTEMI patients (%)
  Sweden 2004
  UK 2004
  Sweden 2007
  UK 2007
  Sweden 2010
  UK 2010
  Sweden 2004-10
  UK 2004-10
45.9 (21.4-63.0)
13.0 (7.6-36.8)
71.4 (62.0-78.5)
40.7 (15.4-80.4)
75.9 (69.0-81.8)
80.6 (69.8-87.1)
61.9 (55.1-71.8)
34.9 (17.1-67.8)
65.9 (56.7-72.8)
88.0 (81.7-93.1)
72.6 (65.1-80.5)
76.1 (69.0-85.1)
76.5 (70.0-82.1)
81.7 (69.6-88.2)
71.1 (66.3-76.5)
77.9 (70.2-84.4)
78.4 (73.3-84.2)
79.8 (71.0-87.8)
86.1 (78.7-89.6)
88.3 (82.9-92.1)
83.1 (73.8-87.2)
91.2 (86.7-94.4)
84.4 (78.2-86.3)
87.0 (82.2-90.9)
25.5 (16.3-29.3)
1.7 (0.0-13.6)
35.7 (29.9-39.8)
19.1 (5.2-32.5)
43.6 (38.5-51.8)
34.9 (19.8-50.5)
34.8 (28.8-39.0)
19.2 (8.1-30.0)
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Fig 1 | Hospital variation in use (median percentage and interquartile range) of treatment 
for st elevation myocardial infarction (steMi) and non- st elevation myocardial infarction 
(nsteMi) by year in sweden and uK. reperfusion percentage among steMi patients was 
weighted by number of steMi admissions to hospital. primary percutaneous coronary 
intervention (pCi) rate was among hospitals that did ≥5 primary pCis during year. 
percentages of revascularisation and anticoagulant were weighted by nsteMi admissions. 
anticoagulant included heparin
doi1 02.00;6/bmj.h;30; | BMJ   2015;101h;30; | the bmj
RESEARCH
4
variation in the provision of primary percutaneous 
coronary intervention coexisted with its temporal 
increase between 2004 and 2010 (interquartile range 
for Sweden 41.6% to 12.8% versus 29.2% to 17.3% for 
UK). Of note, the use of any reperfusion treatment for 
ST elevation myocardial infarction was greater in UK 
hospitals over the study period (and predominantly 
driven by the greater use of thrombolytic treatment); 
whereas between hospital variation in its use 
decreased in Sweden, it increased in the UK. Hospital 
provision of revascularisation for non-ST elevation 
myocardial infarction patients was lower in the UK 
than in Sweden (19.2% v 34.8%), with twice the size 
of variation (interquartile range 21.9% in the UK and 
10.2% in Sweden). Hospital use and practice varia-
tion in provision of anticoagulant for non-ST eleva-
tion myocardial infarction patients were similar in 
Sweden and the UK.
In the pre-discharge prescription of secondary pre-
vention drugs recommended by guidelines, between 
hospital variation was lower for antiplatelet drugs than 
for other secondary prevention drugs in both Sweden 
(interquartile range 4.7% in 2004 and 2.9% in 2010) and 
the UK (4.8% in 2004 and 4.2% in 2010) (fig 2). The pre-
scription of β blockers was higher in Sweden than in the 
UK, with less variation in Swedish hospitals (interquar-
tile range 4.9%) than in UK hospitals (10.1%). Con-
versely, the prescription of angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers and 
statins was higher in UK hospitals than in Swedish hos-
pitals, with somewhat greater variation in Sweden 
(11.6% and 11.9%, respectively) than in the UK (10.1% 
and 4.8%).
inter-hospital variation in 30 day mortality
During the study period, volume weighted 30 day 
mortality in Swedish hospitals (7.0%) was lower than 
in UK hospitals (10.1%) and showed less variation 
(interquartile range 2.1% v 5.7%) (fig 3 ). Thirty day 
mortality and its variation decreased between 2004 
and 2010 from 9.3% (interquartile range 3%) to 6.5% 
(2.8%) in Swedish hospitals and from 12.8% (7.5%) to 
7.6% (5.5%) in UK hospitals (fig 3 ). In Sweden, 
between hospital variation in 30 day mortality was 
greater for ST elevation myocardial infarction (inter-
quartile range 2.5%) than for non-ST elevation myo-
cardial infarction (1.8%), in contrast to the UK where 
the variation was greater for non-ST elevation myo-
cardial infarction (7.1%) than for ST elevation myo-
cardial infarction (5.4%). After control for the 
difference in case mix of admitted patients, the hos-
pital case mix standardised 30 day mortality and its 
variance remained lower in Sweden at 8.4% (inter-
quartile range 2.6%) compared with 9.7% (3.5%) in 
the UK (fig 4).
association between hospital variation in treatment 
and in aMi 30-day mortality
In Sweden, after control for difference in case mix of 
admitted patients, variation in hospital provision of 
guideline recommended treatment together 
explained 28.1% of the between hospital variation in 
30 day mortality from acute myocardial infarction; 
variation in reperfusion therapy for ST elevation 
myocardial infarction and statins prescribed at dis-
charge probably played an important role. Variation 
in hospital treatment explained 21.6% of the varia-
tion in 30 day mortality from acute myocardial infarc-
tion in UK hospitals, where provision of primary 
Any antiplatelet at discharge (%)
  Sweden 2004
  UK 2004
  Sweden 2007
  UK 2007
  Sweden 2010
  UK 2010
  Sweden 2004-10
  UK 2004-10
Dual antiplatelet at discharge (%)
  Sweden 2004
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  UK 2007
  Sweden 2010
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  UK 2004-10
β blocker at discharge (%)
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Statin at discharge (%)
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  UK 2004-10
92.9 (90.2-94.9)
94.6 (91.4-96.2)
95.3 (93.4-96.8)
96.3 (93.9-98.0)
96.3 (94.6-97.5)
97.4 (94.6- 98.8)
95.5 (93.1-96.2)
95.7 (93.4-97.1)
54.7 (44.8-62.5)
0.0 (0.0-0.5)
70.1 (65.3-75.6)
80.0 (73.9-85.8)
78.2 (73.4-83.3)
84.6 (75.8-90.5)
68.9 (63.7-73.4)
60.6 (52.1-70.2)
88.3 (84.4-91.5)
73.9 (68.4-80.0)
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77.4 (71.4-84.8)
90.5 (87.6-93.3)
83.4 (76.5-88.9)
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78.0 (72.9-83.0)
51.9 (42.3-59.5)
81.5 (75.1-87.2)
55.7 (50.7-62.2)
82.9 (77.7-88.6)
63.6 (57.1-69.8)
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Fig 2 | Hospital variation in use (median percentage and interquartile range) of discharge 
drugs for acute myocardial infarction (aMi) by year in sweden and uK. restricted to 
patients who survived beyond discharge and weighted by hospital aMi volume. 
aCei=angiotensin converting enzyme inhibitor; arb=angiotensin receptor blocker
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percutaneous coronary intervention, antiplatelet 
treatment, and statins seemed to be important (sup-
plementary table B).
acute myocardial infarction 30 day mortality by 
hospital treatment quarters
In both Sweden and the UK, lower volume weighted 30 
day mortality rates occurred in hospitals in the highest 
quarter for use of guideline recommended treatments 
(table ). The difference was most notable for primary 
percutaneous coronary intervention, for which com-
parison of hospitals in the lowest and highest quarters 
showed volume weighted 30 day mortality rates of 
10.7% (95% confidence interval 10.1% to 11.3%) versus 
6.6% (6.0% to 7.1%) in Sweden and of 12.7% (12.4% to 
13.0%) versus 5.8% (5.1% to 6.4%) in the UK. The differ-
ence in mortality by quarters of hospital treatment 
decreased after standardisation by patient case mix 
(table of supplementary appendix 3). After adjustment 
for patient case mix, compared with ST elevation myo-
cardial infarction patients admitted to hospitals in the 
lowest quarter, those in hospitals in the highest quarter 
had a 30% lower risk of death at 30 days in Sweden and 
a 32% lower risk in the UK (adjusted odds ratio of 0.70 
(95% confidence interval 0.62 to 0.79) in Sweden and 
0.68 (0.60 to 0.76) in the UK) (fig 5 ). The difference in 
odds ratio was smaller for the comparison of quarter 1 
(lowest) with quarter 2 or 3 hospitals. We also observed 
a smaller difference in odds ratios between hospital 
quarters in any reperfusion for ST elevation myocardial 
infarction and in revascularisation and anticoagulant 
use for non-ST elevation myocardial infarction 
patients. By admission year, a similar trend existed for 
diminishing risk of 30 day mortality for ST elevation 
myocardial infarction patients as the hospital provi-
sion of primary percutaneous coronary intervention or 
any reperfusion treatment increased, especially in the 
UK (supplementary figure A). For discharge drugs, the 
case mix adjusted odds ratios comparing hospitals in 
the highest and lowest quarters for Sweden and the UK 
were, respectively, 0.92 (0.84 to 1.01) and 0.87 (0.83 to 
0.92) for any antiplatelet drug, 0.83 (0.74 to 0.92) and 
0.88 (0.83 to 0.94) for dual antiplatelet treatment, 1.04 
(0.95 to 1.13) and 0.84 (0.80 to 0.88) for β blockers, 0.87 
(0.79 to 0.95) and 0.89 (0.85 to 0.94) for angiotensin 
converting enzyme inhibitors/angiotensin receptor 
blockers, and 0.84 (0.76 to 0.93) and 0.84 (0.81 to 0.88) 
for statins (fig 5).
In the hypothetical scenario, if hospitals in the lower 
three quarters for primary percutaneous coronary 
AMI 30 day mortality (%)
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intervention use had the average case mix standardised 
mortality in the highest quarter, the estimated reduc-
tion in deaths would be 581 in Sweden and 1013 in the 
UK. Likewise, the reduction in deaths would be 573 in 
Sweden and 2274 in the UK if hospitals with lower use 
of dual antiplatelet treatment at discharge reached the 
case mix standardised mortality of hospitals with the 
highest use (supplementary appendix 3).
discussion
This is the first hospital level international comparison 
of the characteristics, treatments, and clinical out-
comes of patients with acute myocardial infarction 
admitted to all hospitals across Sweden and the United 
Kingdom. In both countries, greater use of guideline 
recommended treatment in hospitals was associated 
with smaller variation in practice. Hospitals’ practice 
variation and 30 day mortality were inversely related. 
Patients’ risk of 30 day mortality was lower in hospitals 
in the upper than the lower quarters of treatment use, 
after adjustment for case mix. Comparative analysis 
showed that, in both countries, variation between 
 hospitals in the use of primary percutaneous coronary 
intervention, antiplatelet treatment, and statin at 
 discharge were important in explaining variation in 30 
day mortality. Unmeasured factors accounted for more 
variation in mortality from acute myocardial infarction 
in UK hospitals than in Swedish hospitals. The data 
suggest that more consistent adherence to new treat-
ment guidelines across all hospitals would not only 
reduce practice variation but also deliver improved 
outcomes.
treatment variation
Admission rates for acute myocardial infarction were 
greater in Sweden than in the UK.21-23  This finding was 
similar to the greater rate of ischaemic heart disease 
reported in Sweden than the UK on the basis of dis-
charge data,24  suggesting a higher rate of coronary 
heart disease in hospitals in Sweden than in the UK. 
Hospitals in the UK showed a distinct temporal trend in 
the use of reperfusion treatment; the clinical consen-
sus seemed to favour thrombolytic treatment from 
2004 to 2007, with increasing use of primary percuta-
neous coronary intervention thereafter but not match-
ing Sweden’s use until 2010. The switch towards 
increasing use of primary percutaneous coronary inter-
vention in UK hospitals in 2008 was associated with a 
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significant reduction in inter-hospital variation in 
practice and corresponded with the launch of a 
national policy initiative the same year favouring 
 primary percutaneous coronary intervention.25 26 In 
Sweden, reductions in variation in the use of primary 
percutaneous coronary intervention between hospitals 
diminished in 2006, reflecting a national consensus 
that had moved away from thrombolytic treatment at 
least two years earlier than in the UK. This two year 
delay in implementation of primary percutaneous cor-
onary intervention in the UK seems to have had adverse 
consequences, judging by the favourable 30 day odds 
of mortality for patients with ST elevation myocardial 
infarction receiving treatment in high use compared 
with low use hospitals. Our data suggest that reducing 
between hospital variation in primary percutaneous 
coronary intervention by increasing its use among hos-
pitals with lower adherence has the potential to reduce 
the mortality risk of ST elevation myocardial infarction 
in both countries.
Between hospital variation in the use of guideline 
recommended treatment for non-ST elevation myocar-
dial infarction patients and secondary prevention ther-
apy was less marked than for reperfusion treatment in 
Sweden and the UK. The lowest variation in hospital 
practice was observed in the use of any antiplatelet 
drug, with a between hospital variation of less than 4% 
in both countries, which may be associated with the 
close to complete hospital provision. The adjusted 
odds ratios for patients’ 30 day mortality by quarters of 
hospitals’ use of any antiplatelet treatment were close 
to null. The low levels of inter-hospital variation in any 
antiplatelet drug treatment with little difference in 
mortality between hospitals may provide a useful 
benchmark for other secondary prevention drugs. If 
variations between Swedish and UK hospitals in pre-
scription of all secondary prevention drugs were 
reduced to the levels recorded for any platelet drugs, 
important reductions in variation in mortality could 
probably be achieved.
Mortality variation
A major finding of this study was that hospital level 30 
day mortality for patients with acute myocardial infarc-
tion was not only higher in the UK but also showed 
greater variation than in Sweden. Thus, the distribution 
of case mix standardised 30 day mortality for UK hospi-
tals in figure 4  was broader based and shifted to the 
estimated case mix adjusted 30 day mortality by quarters of hospital treatment
Country
no of 
hospitals
volume weighted mortality (95% Ci) by hospital treatment quarters
Highest Medium-high Medium-low lowest
treatment for st elevation myocardial infarction*
Primary PCI:
 Sweden 86 6.6 (6.0 to 7.1) 7.6 (7.0 to 8.2) 8.2 (7.6 to 8.9) 10.7 (10.1 to 11.3)
 UK 241 5.8 (5.1 to 6.4) 8.2 (7.3 to 9.1) 8.8 (8.0 to 9.6) 12.7 (12.4 to 13.0)
Any reperfusion:
 Sweden 86 7.1 (6.5 to 7.6) 7.7 (7.0 to 8.4) 8.5 (7.8 to 9.2) 10.5 (9.8 to 11.1)
 UK 241 8.0 (7.6 to 8.4) 10.5 (10.0 to 10.9) 12.1 (11.6 to 12.6) 14.4 (13.9 to 15.0)
treatment for non-st elevation myocardial infarction†
Revascularisation:
 Sweden 85 6.1 (5.7 to 6.5) 6.3 (5.8 to 6.7) 8.1 (7.6 to 8.6) 8.6 (8.0 to 9.2)
 UK 240 7.9 (7.4 to 8.5) 9.8 (9.3 to 10.3) 11.7 (11.1 to 12.3) 11.2 (10.6 to 11.8)
Anticoagulant:
 Sweden 84 6.8 (6.4 to 7.3) 6.5 (6.1 to 7.0) 7.9 (7.3 to 8.4) 7.8 (7.3 to 8.4)
 UK 239 7.9 (7.5 to 8.3) 9.8 (9.3 to 10.4) 11.2 (10.5 to 11.8) 12.6 (12.0 to 13.3)
Discharge drugs for acute myocardial infarction‡
Any antiplatelets:
 Sweden 86 6.2 (5.9 to 6.5) 7.0 (6.6 to 7.4) 7.9 (7.4 to 8.3) 9.5 (9.0 to 10.0)
 UK 242 7.9 (7.5 to 8.3) 9.7 (9.2 to 10.1) 11.6 (11.1 to 12.0) 13.2 (12.7 to 13.7)
Dual antiplatelet:
 Sweden 86 6.1 (5.7 to 6.4) 6.8 (6.4 to 7.2) 7.9 (7.4 to 8.3) 9.8 (9.3 to 10.3)
 UK 242 7.7 (7.3 to 8.1) 10.2 (9.7 to 10.7) 11.5 (11.1 to 12.0) 12.9 (12.4 to 13.4)
β blocker:
 Sweden 86 7.1 (6.7 to 7.6) 7.9 (7.3 to 8.4) 7.8 (7.3 to 8.3) 7.8 (7.4 to 8.2)
 UK 242 8.1 (7.7 to 8.5) 9.6 (9.1 to 10.0) 11.5 (11.1 to 12.0) 13.2 (12.7 to 13.7)
ACEI/ARB:
 Sweden 86 6.4 (6.0 to 6.8) 7.0 (6.6 to 7.4) 8.3 (7.8 to 8.8) 9.0 (8.5 to 9.4)
 UK 242 8.9 (8.4 to 9.3) 10.4 (9.9 to 10.8) 11.1 (10.6 to 11.6) 12.1 (11.6 to 12.6)
Statin:
 Sweden 86 6.0 (5.6 to 6.3) 7.2 (6.8 to 7.5) 7.7 (7.3 to 8.1) 9.7 (9.2 to 10.2)
 UK 242 8.4 (8.0 to 8.8) 9.3 (8.8 to 9.8) 10.9 (10.5 to 11.3) 13.7 (13.2 to 14.2)
ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; PCI=percutaneous coronary intervention.
*Mortality reported by quarters of hospital reperfusion treatment.
†Mortality reported by quarters of hospital revascularisation and anticoagulant use.
‡Mortality reported by quarters of hospital discharge drug use.
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right compared with Swedish hospitals. Our data 
 suggest that variations in hospital treatment explained 
about 28% of variation in mortality in Swedish hospi-
tals and 22% in UK hospitals, which was significantly 
greater than the 6% reported by a previous population 
study.4 Although risk differences between hospital 
quarters for secondary prevention drugs were smaller 
than for reperfusion treatment, the potential for deaths 
prevented or deferred is similar or greater for reducing 
variation in use of secondary prevention drugs, which 
benefits all patients with myocardial infarction, than 
for reducing variation in reperfusion treatment, which 
benefits only those with  ST elevation myocardial infarc-
tions (supplementary appendix 3).
policy implications
Other investigators have reported that, beyond varia-
tions in hospital treatment, multiple factors might 
contribute to the residual variation in mortality 
between hospitals, including hospital structure (staff 
expertise, hospital volume, resources),8 10 27-32  pro-
cesses of care (treatment protocol, problem solv-
ing),8 27 29 31 33  and organisational culture.8 29 31 33  We 
found that more patients in both Sweden and the UK 
were admitted to hospitals in the lowest quarters of 
treatment use than to those in the higher quarters. 
Although volume weighted 30 day mortality was 
higher in these hospitals, differences in the case mix 
adjusted odds of 30 day mortality between quarters 
was less striking, suggesting that factors apart from 
underuse of guideline recommended treatments were 
contributing to the excess mortality in these hospitals. 
The low use of guideline recommended treatment in 
such hospitals may be the “canary in the coal mine” 
that signals difficulties in implementing high quality 
care.30  These implementation difficulties might 
include vulnerability of patients and other hospital 
level and regional factors,30 31 emphasising the impor-
tance of looking beyond the prescription of guideline 
recommended drugs in developing quality improve-
ment programmes. In this scenario, quality improve-
ment might best be achieved not only by targeting 
underperforming hospitals but also by the develop-
ment of system-wide initiatives with the aim of deliver-
ing equitable management across all national 
hospitals from time of admission through to discharge 
and beyond. 
Involving patients in the development and commu-
nication of evidence based discharge plans is import-
ant and may improve care and outcomes. This no doubt 
accounted for the success of the UK’s National Service 
Framework for Coronary Heart Disease in 2000,34  but 
Sweden has a more comprehensive nationwide pro-
gramme of quality improvement that includes public 
reporting of hospital mortality, rapid diffusion of new 
technologies,35  more complete use of evidence based 
practice,36  and a more established system for evaluat-
ing and reporting the quality and outcomes of care.37 
This system-wide approach probably accounts, at least 
in part, for the reduced variation in hospital care of 
patients with acute myocardial infarction in Sweden. 
Our results suggest that a national UK strategy aimed 
at increasing the use of guideline recommended treat-
ments in hospitals in the lowest quarter, combined 
with system-wide quality improvement for better 
adherence to guideline recommended treatment, may 
reduce hospitals’ variation in care to Swedish levels 
with a leftward shift of the distribution of case mix 
standardised 30 day hospital mortality in figure 4.
limitations of study
Our study has limitations. Firstly, the contribution that 
other case mix factors unavailable in the data from 
either or both countries, such as angiography, make to 
variability in hospital outcomes cannot be determined. 
These factors at the hospital level may introduce an eco-
logical fallacy when estimating lives saved in hospitals 
in lower treatment use quarters. However, the problem 
of additional confounding arises only insofar as factors 
add prediction beyond the variables already included in 
the model. Additional sensitivity analyses including 
treatment variables in the model gave similar results 
(supplementary figure B). This suggests that study find-
ings based on our approach (using population data 
from ongoing nationwide clinical registries, measures 
based on clinical guidelines and professional led views 
of their importance and comparability, and multilevel 
modelling adjusted for patient level and hospital level 
variables) are accurate and robust.
Secondly, we could not evaluate international differ-
ences in care for acute myocardial infarction before hos-
pital admission that may potentially influence 
in-hospital treatment and outcomes. This is unlikely to 
explain our findings of higher variation in the UK, 
because we found that time from onset of symptoms to 
admission, an indicator of pre-hospital management, 
was similar to that in Sweden.14
Thirdly, using the index admission may underesti-
mate the outcome. However, as the aetiology and prog-
nosis of subsequent acute myocardial infarctions are 
different from the initial episode, we applied the same 
method to identify the index admission in both coun-
tries to reduce the likelihood of including subsequent 
acute myocardial infarctions.
Fourthly, the national registries do not capture all 
patients admitted with acute myocardial infarction, 
and this may be more common in the UK than in 
 Sweden.38  Patients who are not captured tend to be 
older and to have non-ST elevation myocardial infarc-
tion.12  13  38 We did a sensitivity analysis comparing 
the case mix in all acute myocardial infarction 
patients and subgroups of patients aged 80 years and 
above and patients with non-ST elevation myocardial 
infarction in Sweden and the UK (supplementary 
table C). The results showed that differences in case 
mix comparing all patients and patients with a 
greater risk of being missed by the registries in the 
two countries were similar.
Finally, missing values may introduce bias in our 
case mix model. However, we have previously reported 
that estimates for the association between case mix 
variables and 30 day mortality, based on multiple 
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imputed data, were verified by estimates based on com-
plete case analysis.14
need for further research
International comparisons are an integral component of 
contemporary research on prognosis.39  They are infor-
mative about the relative performance of healthcare sys-
tems, and further comparisons with other national 
registries are now needed, including those in the United 
States,40  China,41  and New Zealand.42  In these coun-
tries, participation in registries is often voluntary and 
research will be needed to understand the effect of hos-
pital and case selection. Each patient with acute myo-
cardial infarction may have had various  measurements 
taken for therapeutic decisions and monitoring. This 
information is recorded in diverse electronic health 
record systems before, during, and after hospital admis-
sion. Linkage to national electronic health records has 
been shown to effectively enable studies to investigate 
and compare fatal and non-fatal events occurring along 
the care pathway,43  including primary care,44  hospital 
care,14 45  and post-acute phase care.46 47 Increasing avail-
ability of linked data on existing health measurements 
during the care process can facilitate further in-depth 
and thorough international comparisons for better out-
comes for patients. Our findings also have policy impli-
cations for identifying, reporting, and thereafter 
reducing inter-hospital variability in healthcare. Further 
work is necessary to determine the competing benefits 
of targeting underperforming hospitals or developing a 
national programme of quality improvement for more 
complete use of treatment for acute myocardial infarc-
tion across all hospitals.
Conclusions
Between hospital variation in guideline recommended 
treatment of acute myocardial infarction was greater in 
the United Kingdom than in Sweden. This was associated 
with, and may partly account for, the higher 30 day mor-
tality in UK hospitals and greater variation in that mor-
tality. A system-wide national programme modelled on 
Sweden’s quality improvement programme has the 
potential to reduce unacceptable variation in practice if 
implemented across all UK hospitals, with an anticipated 
reduction in 30 day mortality towards Swedish levels.
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